leadf
logo-loader
view4D pharma plc

4d Pharma's Duncan Peyton updates as enrolment begins for Phase II COVID-19 study

4d Pharma's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients in hospital with COVID-19 is now open to enrolment. Dosing of the first patients should begin shortly and Peyton says that as MRx-4DP0004 is a live biotherapeutic it's expected to show a favourable safety profile.

Quick facts: 4D pharma plc

Price: 99 GBX

LSE:DDDD
Market: LSE
Market Cap: £130.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4d pharma reveal positive data from phase II trial of treatment for...

4D pharma plc's (LON:DDD) Alex Stevenson speaks to Proactive London's Katie Pilbeam about the company's latest report which showed positive data for its phase II trial of its live biotherapeutic for irritable bowel syndrome (IBS). He says the results provide the foundation for continued...

1 week, 5 days ago

2 min read